Sona Nanotech Inc C.SONA

Alternate Symbol(s): SNANF

Technology Scientific & Technical Instruments

Sona Nanotech Inc. is a nanotechnology life sciences company, which is engaged in developing targeted hyperthermia therapy. The Company has developed multiple methods for the manufacturing of various types of gold nanoparticles (GNR). It is engaged in research and development of its technology for use in multiplex diagnostic testing platforms and advanced biomedical applications. Its gold nanotechnologies are adapted for use in applications, as a safe and delivery system for multiple medical treatments, for the approval of various regulatory boards, including Health Canada and the Food and Drug administration (FDA). Its gold nanorod particles are manufactured without the use of cetyltrimethylammonium bromide (CTAB), eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. The Company is focused on the development of a pre-clinical nanomedical therapy for the treatment of cancer using its biocompatible GNR.

CSE:SONA - Post by User

Sona Nanotech Inc > An other tweet

<< Previous

Bullboard Posts

Next >>

Comment by Pandoraon Jan 22, 2021 6:16pm

158 Views

Post# 32366086

RE:RE:RE:RE:An other tweet

So are you suggesting this news release was just straight outright B.S. by the company?? Or would you temper that by saying you're just not really sure?

December 31, 2020

Halifax, Nova Scotia--(Newsfile Corp. - December 31, 2020) - Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company", "Sona") a developer of rapid, point-of-care diagnostic tests, has been granted CE Mark status for its rapid, COVID-19 antigen test. The CE Mark declares the conformity of the Sona test with EU regulations and allows Sona to commercialize its test throughout Europe and potentially other territories in which the CE Mark is recognized.

The Company intends to begin selling its test as a screening tool for organizations wishing to screen individuals in high-risk congregate settings in which testing could quickly identify persons with a SARS-CoV-2 infection to inform infection prevention and control measures to reduce risk of transmission. Individuals who have symptoms of COVID-19 or who have had close contact with someone with confirmed COVID-19 should be considered as candidates for screening. As a rapid screening test, all results should be assessed in the context of the local prevalence of the virus and considered 'presumed' positive or negative until confirmed by a physician.

With its CE Mark secured, the Company is now able to take firm orders in territories accepting a CE Mark and make corresponding manufacturing commitments from its contract manufacturer in the United Kingdom. The Company is currently also in the process of technology transfer to a second manufacturer, in North America. The Company will report quarterly on sales volumes and will update the market as material developments occur.

TheeRook wrote: Better check that CE Mark , it looks like its just for products like a toaster

A health test needs The CE-IVD mark is in conformance with the European Union in ivitro diagnostic directive.

Advanta Dx will be one of the first saliva-based COVID-19 tests to be made available throughout Europe. Fluidigm plans to sell Advanta Dx for as little as 5 euros per test. There's a big opportunity for the company: The total European market for COVID-19 testing this year is projected to be between $5 billion and $7 billion.

dart321 wrote: You hear that massive sucking sound getting louder by the minute. That is the sound of all the tests and vaccines being manufactured in the EU being sucked up by the Biden defence production act.